Publications by authors named "Pascale Fouqueray"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

738

Total Likes

67

Extended Reach

53,085

Social Features

13
M
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Sophie Hallakou-Bozec, Guillaume Vial, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, Anne-Laure Borel, Eric Fontaine, David E Moller

Diabetes Obes Metab· March 2021

Videos about Article: user

1 8 12 12

View All Article and Social Media Activity
I
Imeglimin: A Clinical Pharmacology Review.
Clémence Chevalier, Pascale Fouqueray, Sébastien Bolze

Clin Pharmacokinet· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Stephen A Harrison, Carole Thang, Sébastien Bolze, Sheila Dewitt, Sophie Hallakou-Bozec, Pascale Fouqueray

J Hepatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
Pierre Theurey, Carole Thang, Valdis Pirags, Andrea Mari, Giovanni Pacini, Pascale Fouqueray

Endocrinol Diabetes Metab· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.
Pascale Fouqueray, Clémence Chevalier, Sébastien Bolze

Clin Drug Investig· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy.
Pierre-Axel Monternier, Parveen Parasar, Pierre Theurey, Pascale Gluais Dagorn, Navtej Kaur, Pascale Fouqueray

J Pharmacol Exp Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Caroline Reilhac, Julie Dubourg, Carole Thang, Jean-Marie Grouin, Pascale Fouqueray

Diabetes Obes Metab· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Julie Dubourg, Pascale Fouqueray, Damien Quinslot, Jean-Marie Grouin, Kohei Kaku

Diabetes Obes Metab· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Pierre Theurey, Guillaume Vial, Eric Fontaine, Pierre-Axel Monternier, Pascale Fouqueray

Physiol Rep· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.
Pascale Fouqueray, Sebastien Bolze, Julie Dubourg, Sophie Hallakou-Bozec, Pierre Theurey

Cell Rep Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Kenneth Cusi, Naim Alkhouri, Stephen A Harrison, Pascale Fouqueray, David E Moller

Lancet Gastroenterol Hepatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.
Sophie Hallakou-Bozec, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, David E Moller

PLoS One· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deuterium-Stabilized ()-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity.
Vincent Jacques, Sébastien Bolze, Sophie Hallakou-Bozec, Anthony W Czarnik, Ajit S Divakaruni, Pascale Fouqueray

Hepatol Commun· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.
Clémence Chevalier, Julie Dubourg, Sébastien Bolze, Pascale Fouqueray

Clin Pharmacokinet· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean-Marie Grouin, Kohjiro Ueki

Diabetes Care· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Julie Dubourg, Kohjiro Ueki, Jean-Marie Grouin, Pascale Fouqueray

Diabetes Obes Metab· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.
Clémence Chevalier, Sandrine Perrimond-Dauchy, Julie Dubourg, Pascale Fouqueray, Sébastien Bolze

Eur J Drug Metab Pharmacokinet· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans.
Chevalier Clémence, Pascale Fouqueray, Bolze Sébastien

Drug Metab Dispos· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.
Pascale Fouqueray, Sandrine Perrimond-Dauchy, Sébastien Bolze

Clin Pharmacokinet· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
Julie Dubourg, Sandrine Perrimond-Dauchy, Mathieu Felices, Sébastien Bolze, Pascal Voiriot, Pascale Fouqueray

Eur J Clin Pharmacol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.
Rachel J Perry, Rebecca L Cardone, Max C Petersen, Dongyan Zhang, Pascale Fouqueray

Am J Physiol Endocrinol Metab· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Pascale Fouqueray, Valdis Pirags, Michaela Diamant, Guntram Schernthaner, Harold E Lebovitz

Diabetes Care· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Pascale Fouqueray, Valdis Pirags, Silvio E Inzucchi, Clifford J Bailey, Guntram Schernthaner

Diabetes Care· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis